Cargando…

How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?

Objective: To evaluate the clinicopathological characteristics of grade group 1 (GG1) prostate cancer in Korean populations. Methods: We retrospectively analyzed 492 consecutive radical prostatectomy specimens from our institution, which included those from 322 men with clinical GG1 and 170 with cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Mun Su, Choi, Yeong Jin, Lee, Young Sub, Yoon, Byung Il, Ha, U-Syn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262215/
https://www.ncbi.nlm.nih.gov/pubmed/34257593
http://dx.doi.org/10.3389/pore.2021.629489
_version_ 1783719147751866368
author Chung, Mun Su
Choi, Yeong Jin
Lee, Young Sub
Yoon, Byung Il
Ha, U-Syn
author_facet Chung, Mun Su
Choi, Yeong Jin
Lee, Young Sub
Yoon, Byung Il
Ha, U-Syn
author_sort Chung, Mun Su
collection PubMed
description Objective: To evaluate the clinicopathological characteristics of grade group 1 (GG1) prostate cancer in Korean populations. Methods: We retrospectively analyzed 492 consecutive radical prostatectomy specimens from our institution, which included those from 322 men with clinical GG1 and 170 with clinical GG2 tumors between years 2009 and 2018. The incidence of Gleason score (GS) upgrading, extraprostatic extension (EPE), and seminal vesicle invasion (SVI) were evaluated in patients with clinical GG1. In pathological GG1 cases, the distribution of adverse pathological features including EPE, lymphovascular invasion (LVI), perineural invasion (PNI), and biochemical recurrence (BCR) was analyzed. Results: Altogether, 78 (24.2%) out of 322 men in the clinical GG1 group demonstrated upgrading of GS, including 19 men with pathological Gleason score 4 + 3 = 7 and 6 with ≥ pathological Gleason score 4 + 4 = 8 cases. EPE was found in 37 (11.5%) and 22 (8.9%) men in clinical GG1 and pathological GG1 group, respectively. The incidence of LVI and PNI in the pathological GG1 cases was 2.8% (n = 7) and 28.6% (n = 71), respectively. BCR was observed in 4 men in pathological GG1 T2 (n = 226) and 2 men in GG1 T3 (n = 22) group. When we compared the pathological features between pathological GG1 T3 vs. GG2 T2, there was no statistical differences in the incidence of LVI and PNI between the two groups. Conclusions: Contrary to the current concept that GG1 is almost always clinically insignificant, it seems that GG1 still possess its respectable position as a group of cancer with aggressiveness. These findings should be kept in mind when deciding on treatment options for prostate cancer patients in the Asian populations.
format Online
Article
Text
id pubmed-8262215
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82622152021-07-12 How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer? Chung, Mun Su Choi, Yeong Jin Lee, Young Sub Yoon, Byung Il Ha, U-Syn Pathol Oncol Res Society Journal Archive Objective: To evaluate the clinicopathological characteristics of grade group 1 (GG1) prostate cancer in Korean populations. Methods: We retrospectively analyzed 492 consecutive radical prostatectomy specimens from our institution, which included those from 322 men with clinical GG1 and 170 with clinical GG2 tumors between years 2009 and 2018. The incidence of Gleason score (GS) upgrading, extraprostatic extension (EPE), and seminal vesicle invasion (SVI) were evaluated in patients with clinical GG1. In pathological GG1 cases, the distribution of adverse pathological features including EPE, lymphovascular invasion (LVI), perineural invasion (PNI), and biochemical recurrence (BCR) was analyzed. Results: Altogether, 78 (24.2%) out of 322 men in the clinical GG1 group demonstrated upgrading of GS, including 19 men with pathological Gleason score 4 + 3 = 7 and 6 with ≥ pathological Gleason score 4 + 4 = 8 cases. EPE was found in 37 (11.5%) and 22 (8.9%) men in clinical GG1 and pathological GG1 group, respectively. The incidence of LVI and PNI in the pathological GG1 cases was 2.8% (n = 7) and 28.6% (n = 71), respectively. BCR was observed in 4 men in pathological GG1 T2 (n = 226) and 2 men in GG1 T3 (n = 22) group. When we compared the pathological features between pathological GG1 T3 vs. GG2 T2, there was no statistical differences in the incidence of LVI and PNI between the two groups. Conclusions: Contrary to the current concept that GG1 is almost always clinically insignificant, it seems that GG1 still possess its respectable position as a group of cancer with aggressiveness. These findings should be kept in mind when deciding on treatment options for prostate cancer patients in the Asian populations. Frontiers Media S.A. 2021-04-13 /pmc/articles/PMC8262215/ /pubmed/34257593 http://dx.doi.org/10.3389/pore.2021.629489 Text en Copyright © 2021 Chung, Choi, Lee, Yoon and Ha. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Chung, Mun Su
Choi, Yeong Jin
Lee, Young Sub
Yoon, Byung Il
Ha, U-Syn
How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title_full How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title_fullStr How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title_full_unstemmed How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title_short How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?
title_sort how much reliable is the current belief on grade group 1 prostate cancer?
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262215/
https://www.ncbi.nlm.nih.gov/pubmed/34257593
http://dx.doi.org/10.3389/pore.2021.629489
work_keys_str_mv AT chungmunsu howmuchreliableisthecurrentbeliefongradegroup1prostatecancer
AT choiyeongjin howmuchreliableisthecurrentbeliefongradegroup1prostatecancer
AT leeyoungsub howmuchreliableisthecurrentbeliefongradegroup1prostatecancer
AT yoonbyungil howmuchreliableisthecurrentbeliefongradegroup1prostatecancer
AT hausyn howmuchreliableisthecurrentbeliefongradegroup1prostatecancer